Take the next step toward safer, sustainable weight loss schedule a consultation with our medical team at Passion Health Primary Care today.
More serious but less common adverse effects observed in trials or associated with this drug class include: Increased heart rate , a class effect seen with GLP-1 receptor agonists [15] [12] Gallbladder disease , including gallstones (cholelithiasis), which has been associated with rapid weight loss and incretin-based therapies more broadly
In clinical trials, participants lost an average of 14.9% of their body weight over 68 weeks (published in the New England Journal of Medicine)
1,2 Retatrutide isnt legally available in the UK as of May 2026
The comparison between phentermine and GLP-1 medications and the phentermine versus semaglutide comparison may also be relevant for patients exploring lower-cost pharmaceutical alternatives when GLP-1 access becomes restricted
Good communication goes a long way toward managing expectations and mitigating risk
/assets/images/provider/photos/2814339.jpeg)
